Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sugammadex dosing by total versus corrected body weight for reversal of deep rocuronium-induced neuromuscular blockade in morbidly obese patients undergoing laparoscopic bariatric surgery
ChiCTR1900028652Phase 4Recruiting
- Sponsor
- The Fourth Hospital of China Medical University
- Start
- Jan 2020
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of Sugammadex in neuromuscular block (NMB) (3 arms), sponsored by The Fourth Hospital of China Medical University. Primary endpoints: Time to TOF ratio of 0.9 and All adverse events. Started Jan 2020; status: recruiting.
02
Drugs
Sugammadex
03
Conditions
neuromuscular block (NMB)
Beyond the preview
Go deeper on ChiCTR1900028652.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900028652.